How Does Sarepta Therapeutics Company Work?

Sarepta Therapeutics Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

How is Sarepta Therapeutics reshaping Duchenne treatment?

Sarepta vaulted to the forefront of DMD care in 2024–2025 after ELEVIDYS received FDA approval, priced near $3.2 million per single-dose treatment, complementing its exon-skipping PMO franchise and making it the most commercially scaled DMD pure-play.

Operating as a precision genetic medicines company, Sarepta spans RNA-targeted therapies, AAV gene therapy and gene editing, funding R&D through product revenues and partnerships while scaling manufacturing and managing payer access to monetize a concentrated rare-disease portfolio.

How Does Sarepta Therapeutics Company Work? Learn strategic context in Sarepta Therapeutics Porter's Five Forces Analysis

Sarepta Therapeutics focuses on precision genetic medicines for rare neuromuscular disorders, primarily Duchenne muscular dystrophy (DMD), combining exon-skipping PMOs and AAV gene therapy to enable dystrophin production across mutation-defined patient groups and broader populations.

Core product portfolio

Three exon-skipping PMOs—Exondys 51 (exon 51), Vyondys 53 (exon 53), and Amondys 45 (exon 45)—target mutation-amenable subgroups; ELEVIDYS (delandistrogene moxeparvovec-rokr) is an AAVrh74 micro-dystrophin gene therapy for broader DMD populations.

Value proposition

Sarepta creates value by offering both chronic PMO options and a one-time gene therapy, enabling tailored physician choices across disease stages and patient phenotypes while addressing payer models for ultra-rare diseases.

Integrated operations

Operations span discovery, clinical development, CMC scale-up and commercial execution; gene-therapy workflows include plasmid production, AAV vector manufacturing, fill-finish, cold-chain logistics and treatment-center enablement with REMS and monitoring.

Manufacturing and supply resilience

Manufacturing uses internal facilities plus specialized CDMOs and analytical partners, building redundancy for high-titer AAV supply; recent public reporting (2024–2025) highlights stepped-up capacity investments and quality controls to support ELEVIDYS roll-out.

Commercial model and partnerships balance direct U.S. commercialization with ex-U.S. alliances; ELEVIDYS global commercialization is partnered with Roche to leverage regulatory, market-access and distribution infrastructure once regional approvals are obtained.

Competitive differentiators

Sarepta’s advantages derive from deep DMD domain expertise, an established treated patient base, strong neuromuscular-clinic relationships, integrated real-world evidence and registry programs, and CMC know-how for AAV.

• Established PMO franchise treating thousands of patients globally as of 2024–2025
• ELEVIDYS approval (U.S. FDA granted in 2023) positions a one-time gene therapy alongside chronic PMOs
• Commercial readiness includes payer engagement tailored to ultra-rare economics and outcomes-based arrangements
• Global alliance with Roche accelerates ex-U.S. access and reimbursement efforts

For detailed commercial strategy and market positioning analysis see Marketing Strategy of Sarepta Therapeutics.

Sarepta Therapeutics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Revenue for Sarepta Therapeutics is driven primarily by product sales of DMD therapies, with a growing mix from gene therapy and collaboration economics; FY2024 market-reported total revenue ranged roughly between $1.4–$1.7 billion, led by the PMO franchise while ELEVIDYS scaled as treatment centers came online.

Product sales: PMOs

PMO franchise produces recurring per-patient annual revenue, representing the majority of 2024 sales as treatments are billed year-over-year and reimbursed by payers.

Product sales: ELEVIDYS

ELEVIDYS is a one-time gene therapy with a U.S. list price near $3.2 million; revenues scale as centers and payer pathways expand following label changes in 2024.

U.S. vs. ex-U.S. mix

Sales in 2024 were predominantly U.S.-based; international growth is expected via Roche, where Sarepta recognizes royalties, milestones and limited ex-U.S. sales-related economics.

Collaboration revenue

Roche 2019 alliance delivered significant upfront cash and equity; future non-product revenue includes development, regulatory and sales milestones plus tiered royalties on ex-U.S. ELEVIDYS.

Access and pricing strategies

Sarepta uses outcomes-aligned contracts and centers-of-excellence to ease administration; PMOs typically net mid-to-high six-figure annual pricing per patient, varying by payer and contract.

Revenue mix evolution

Post-June 2024 FDA label expansion for ELEVIDYS (ambulatory and non-ambulatory patients 4+) shifts mix toward a blended portfolio; ex-U.S. royalties and milestones may grow as international launches progress.

Sarepta Therapeutics monetization combines recurring PMO sales, high-value one-time gene therapy receipts, and collaboration-derived milestone/royalty streams; investors should monitor adoption rates for ELEVIDYS, payer agreements, and Roche-partnered ex-U.S. milestones for revenue trajectory.

Key revenue drivers and metrics

Primary levers that will determine near-term and medium-term revenue outcomes:

• U.S. uptake and reimbursement pathways for ELEVIDYS and PMOs
• Number of certified treatment centers and time-to-treatment for gene therapy
• Roche-mediated ex-U.S. approvals, launches, and milestone triggers
• Contracting approaches: outcomes-based agreements and payer-specific pricing

For broader context on market positioning and competitors, see Competitors Landscape of Sarepta Therapeutics

Sarepta Therapeutics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Sarepta Therapeutics built a recurring-revenue base with sequential U.S. approvals from 2016–2021 and leveraged gene‑therapy approvals and partnerships to expand its Duchenne muscular dystrophy (DMD) addressable market and commercial footprint.

Regulatory milestones

Between 2016 and 2021 Sarepta secured U.S. approvals for Exondys 51, Vyondys 53, and Amondys 45, creating steady revenue from exon‑skipping therapies and strengthening DMD center relationships.

Global commercialization partnership

In 2019 Sarepta partnered with Roche to commercialize SRP‑9001 (ELEVIDYS) outside the U.S., combining Sarepta gene‑therapy expertise with Roche’s global scale and payer network.

ELEVIDYS approvals and label expansion

ELEVIDYS received U.S. approval in June 2023 and a label expansion in June 2024 after EMBARK data, enabling treatment for ambulatory and non‑ambulatory patients aged 4+, materially expanding the target population.

Manufacturing and supply‑chain scale

Sarepta invested in AAV capacity, analytics, and redundancy to raise patient throughput and reduce site bottlenecks; capacity buildouts aimed to support commercial demand following ELEVIDYS launch.

Market access and safety infrastructure reinforced adoption: rapid payer coverage in 2023–2024 using outcomes‑based constructs and strengthened post‑marketing data collection reduced access friction for eligible patients.

Competitive edge and strategic positioning

Sarepta’s competitive advantages derive from first‑mover leadership in DMD gene therapy, a multi‑modality portfolio spanning chronic exon‑skipping drugs and one‑time AAV gene therapies, plus deep KOL and treatment‑center relationships.

• First‑mover AAV gene‑therapy advantage with ELEVIDYS U.S. approval and label expansion, expanding addressable market by moving into non‑ambulatory patients aged 4+.
• Multi‑modality pipeline: antisense oligonucleotides (exon skipping) and gene therapy programs diversify revenue and clinical risk.
• Operational focus on manufacturing scale and analytics to support anticipated commercial demand and reduce site constraints on treatment throughput.
• Robust safety‑management and post‑marketing evidence generation to meet regulatory confirmatory requirements and payer expectations for AAV therapies.

Key commercial and financial context: exon‑skipping products established recurring revenue since 2016; ELEVIDYS commercialization in the U.S. launched June 2023 with label expansion June 2024; partnerships (Roche ex‑U.S.) and payer outcomes agreements in 2023–2024 accelerated access while manufacturing investments targeted higher AAV throughput. See Target Market of Sarepta Therapeutics for related market analysis.

Sarepta Therapeutics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Sarepta Therapeutics leads the Duchenne muscular dystrophy (DMD) market with an approved gene therapy and three exon-skipping drugs covering roughly 25–30% of patients; U.S. share is substantial and ex-U.S. expansion is expected via Roche partnerships pending EU/UK/Japan approvals.

Industry Position

Sarepta company overview: market leader in DMD across modalities with ELEVIDYS (SRP-9001) as the only FDA-approved gene therapy and three approved PMO exon-skipping drugs for exons 51, 53 and 45.

Commercial Footprint

U.S. treated-patient market share is strong due to portfolio breadth and Duchenne centers coverage; Roche collaboration aims to expand Sarepta gene therapy reach in Europe, the UK and Japan.

Key Risks

Primary risks include uncertainty on ELEVIDYS durability and long-term safety, AAV class toxicities (hepatotoxicity, immunogenicity), and manufacturing scale/vector supply constraints.

Financial Sensitivities

Profitability depends on ELEVIDYS uptake, persistence of PMO exon-skipping drugs, and milestone/royalty receipts from ex-U.S. approvals; R&D and manufacturing investments remain substantial.

Near-term catalysts and outlook focus on international approvals, label refinements, lifecycle strategies for dosing/retreatment, and pipeline readouts in limb-girdle muscular dystrophies and gene-editing programs.

Risks, Catalysts, and Strategic Priorities

Management highlights scaling treatment capacity, payer alignment and global execution to convert clinical leadership into durable revenues; concentration in DMD remains a business risk.

• Regulatory/clinical uncertainty for gene therapy durability and long-term safety
• AAV class risks: hepatotoxicity and immune responses documented in 2020–2024 literature
• Manufacturing and vector supply limits could constrain commercial roll-out
• Competition from next-gen gene therapies, RNA-based rivals and gene-editing programs

Sustained revenue growth depends on ELEVIDYS penetration, successful ex-U.S. launches with Roche (expected regulatory filings/decisions in EU/UK/Japan), pipeline diversification beyond DMD, and execution on manufacturing scale; see company history here: Brief History of Sarepta Therapeutics

Sarepta Therapeutics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔